Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
of $805M–$825M (about 4% YoY ) and adjusted EBITDA of $455M–$475M (~ 1% YoY ), with ADHD franchise Jornay PM expected to generate $190M–$200M (~31% YoY at midpoint). The company agreed to buy AZSTARYS from Corium for $650M upfront plus up to $135M in milestones; management says the ADHD product is complementary to Jornay PM, is supported by six Orange Book patents (mostly expiring Dec 2037), generated 760,000 prescriptions in 2025, and is expected to deliver $50M net revenue in H2 2026 and be immediately accretive. To fund the deal Collegium put in place a new syndicated facility— $580M term loan $300M delayed draw and $100M revolver —planning to use the delayed draw plus cash to pay AZSTARYS' upfront and expects leverage of about 2x at closing; commercially it is expanding the ADHD sales force from 125 to 180 reps while expecting modest pressure in the pain portfolio due to Nucynta generic dynamics. Interested in Collegium Pharmaceutical, Inc.? Here are five stocks we like bett
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium to Participate in Upcoming Investor ConferencesGlobeNewswire
- 1 Value Stock on Our Buy List and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
- 2 Profitable Stocks to Consider Right Now and 1 We Question [Yahoo! Finance]Yahoo! Finance
- Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers [Yahoo! Finance]Yahoo! Finance
- Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD [Yahoo! Finance]Yahoo! Finance
COLL
Earnings
- 2/26/26 - Beat
COLL
Sec Filings
- 4/7/26 - Form ARS
- 4/7/26 - Form DEF
- 4/7/26 - Form 8-K
- COLL's page on the SEC website